AMILI, a Singapore-based precision gut microbiome company, said Wednesday it has raised$10.5 million in Series A funding to accelerate its business expansion in Southeast Asia and Greater Asia. The round was led by Vulcan Capital, the investment arm of the late Microsoft Corp co-founder Paul Allen that invests in category-leading technology, internet, and life sciences companies.